Robert I. Nicholson

Active 1975–2015

95
Papers
19,103
Citations
84
h-index
95
i10-index

Citations

Citations per year for Robert I. Nicholson1976: 1 citations1977: 1 citations1978: 3 citations1979: 1 citations1980: 6 citations1981: 5 citations1982: 6 citations1983: 5 citations1984: 19 citations1985: 14 citations1986: 5 citations1987: 20 citations1988: 10 citations1989: 15 citations1990: 11 citations1991: 16 citations1992: 12 citations1993: 8 citations1994: 31 citations1995: 36 citations1996: 34 citations1997: 48 citations1998: 56 citations1999: 78 citations2000: 87 citations2001: 96 citations2002: 98 citations2003: 240 citations2004: 219 citations2005: 303 citations2006: 220 citations2007: 253 citations2008: 292 citations2009: 251 citations2010: 237 citations2011: 277 citations2012: 200 citations2013: 205 citations2014: 152 citations2015: 149 citations2016: 138 citations2017: 160 citations2018: 100 citations2019: 392 citations2020: 340 citations2021: 300 citations2022: 223 citations2023: 183 citations2024: 214 citations2025: 95 citations2026: 3 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,997 citing papers, 28.8% of this breakdownUnited Kingdom: 764 citing papers, 11% of this breakdownChina: 526 citing papers, 7.6% of this breakdownItaly: 327 citing papers, 4.7% of this breakdownGermany: 301 citing papers, 4.4% of this breakdownCanada: 244 citing papers, 3.5% of this breakdownAustralia: 238 citing papers, 3.4% of this breakdownFrance: 221 citing papers, 3.2% of this breakdownJapan: 198 citing papers, 2.9% of this breakdownSpain: 168 citing papers, 2.4% of this breakdownNetherlands: 155 citing papers, 2.2% of this breakdownIndia: 135 citing papers, 2% of this breakdown
0%28.8%Other 23.9%

Fields

  • Biochemistry, Genetics and Molecular Biology43.1%
  • Medicine40.9%
  • Nursing6%
  • Materials Science2.6%
  • Immunology and Microbiology1.7%
  • Chemistry1.6%
  • Other4.1%

Topics

  • HER2/EGFR in Cancer Research6.8%
  • Estrogen and related hormone effects5.4%
  • Breast Cancer Treatment Studies4.8%
  • Cancer-related Molecular Pathways3.1%
  • Cancer Cells and Metastasis2.5%
  • Trace Elements in Health2.4%
  • Other75%

Coauthors

All papers

Open in search
  1. EGFR and cancer prognosis

    Authors: , , - European Journal of Cancer 2001 cited by 2,146

  2. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

    Authors: , , - British Journal of Cancer 2004 cited by 407

  3. Protein Kinase CK2 Triggers Cytosolic Zinc Signaling Pathways by Phosphorylation of Zinc Channel ZIP7

    Authors: , , , , - Science Signaling 2012 cited by 268

  4. ZIP7-Mediated Intracellular Zinc Transport Contributes to Aberrant Growth Factor Signaling in Antihormone-Resistant Breast Cancer Cells

    Authors: , , , , , - Endocrinology 2008 cited by 237

  5. Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer

    Authors: , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 cited by 137

  6. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

    Authors: , , , , , , , , , , , - Breast Cancer Research and Treatment 2009 cited by 239

  7. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes

    Authors: , , , , , , , , , , , - European Journal of Cancer 2007 cited by 256

  8. The Emerging Role of the LIV-1 Subfamily of Zinc Transporters in Breast Cancer

    Authors: , , , , , , , - Molecular Medicine 2007 cited by 229

  9. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer

    Authors: , , , , , , , , , , , , - Nature Communications 2015 cited by 134

  10. Expression of luminal and basal cytokeratins in human breast carcinoma

    Authors: , , , , , , , - The Journal of Pathology 2004 cited by 599

  11. Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor–Positive Phenotype

    Authors: , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 328

  12. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

    Authors: , , , , , , , , , , , , - Breast Cancer Research and Treatment 2012 cited by 99

  13. The LZT proteins; the LIV-1 subfamily of zinc transporters

    Authors: , - Biochimica et Biophysica Acta (BBA) - Biomembranes 2003 cited by 257

  14. Structure–function analysis of a novel member of the LIV‐1 subfamily of zinc transporters, ZIP14

    Authors: , , , - FEBS Letters 2004 cited by 176

  15. Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

    Authors: , , , , , , , , , , , , , , - Cancer Research 2008 cited by 408

  16. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation

    Authors: , , , - Trends in Molecular Medicine 2009 cited by 222

  17. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.

    Authors: , , , , , , , - 1999 cited by 217

  18. Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor

    Authors: , , , , - Endocrinology 2005 cited by 186

  19. Structure-function analysis of HKE4, a member of the new LIV-1 subfamily of zinc transporters

    Authors: , , , - Biochemical Journal 2004 cited by 139

  20. 2012 White Paper on Recent Issues in Bioanalysis And Alignment of Multiple Guidelines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert I. Nicholson, Eric Ormsby, Jeffrey Sailstad, Lauren Stevenson, Daniel Tang, Jan Welink, C.T. Viswanathan, Laixin Wang, Eric Woolf, Eric Yang - Bioanalysis 2012 cited by 101

  21. 2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings from Audits and Inspections

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Graeme Young - Bioanalysis 2011 cited by 93

  22. A prognostic index in primary breast cancer

    Authors: , , , , , , , - British Journal of Cancer 1982 cited by 717

  23. Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells

    Authors: , , , , , , , , - Endocrinology 2003 cited by 534

  24. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation

    Authors: , , , , , , , - International Journal of Cancer 2005 cited by 264